Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1754171 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBALDH1A1NPC1RECQL | |
| SCHEMBL256792 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBALDH1A1NPC1RECQL | |
| SCHEMBL13542547 | 0.85 | GPR139 (0.48) | POLBALDH1A1KMT2ACTSKCTSS | |
| SCHEMBL25546987 | 0.85 | GPR139 (0.48) | POLBALDH1A1KMT2ACTSKCTSS | |
| SCHEMBL3502879 | 0.85 | CTSK (0.48) | KMT2ACTSKCTSS | |
| SCHEMBL23205455 | 0.85 | GPR139 (0.48) | POLBALDH1A1KMT2ACTSKCTSS | |
| SCHEMBL15048272 | 0.85 | CTSK (0.48) | KMT2ACTSKCTSS | |
| SCHEMBL27788730 | 0.85 | CTSK (0.48) | KMT2ACTSKCTSS | |
| SCHEMBL3502878 | 0.85 | CTSK (0.48) | KMT2ACTSKCTSS | |
| SCHEMBL8415289 | 0.85 | ALDH1A1 (0.48) | SMN1; SMN2POLBALDH1A1LMNACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-12479857-B2 | Bax inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| WO-2025137267-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4537905-A2 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| CN-1863779-A | Novel indazole derivative | UBE INDUSTRIES (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1716150-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005070932-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| CN-1630633-A | N-biphenylmethylaminocycloalkane carboxamide derivatives with substituents on the methyl group thereof as bradykinin antagonists | MERCK & CO INC (US) | 2005-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | SMN1; SMN2 1412/4885POLB 2536/4885ALDH1A1 4585/4885 |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | SMN1; SMN2 3606/4885POLB 57/4885ALDH1A1 792/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | SMN1; SMN2 1205/4885POLB 1018/4885ALDH1A1 3935/4885 |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MUSK, MAPT | SMN1; SMN2 10/4885POLB 2525/4885ALDH1A1 2475/4885 |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | SMN1; SMN2 3606/4885POLB 57/4885ALDH1A1 792/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | SMN1; SMN2 21/4885POLB 2863/4885ALDH1A1 996/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | SMN1; SMN2 3396/4885POLB 3661/4885ALDH1A1 4101/4885 |
| US-20070129404-A1 | Novel indazole derivatives | CIT, ROCK1, ROCK2 | SMN1; SMN2 4865/4885POLB 3966/4885ALDH1A1 2147/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | SMN1; SMN2 2048/4885POLB 2338/4885ALDH1A1 4621/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | SMN1; SMN2 1134/4885POLB 1451/4885ALDH1A1 3742/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | SMN1; SMN2 2248/4885POLB 2490/4885ALDH1A1 4714/4885 |
| US-12479857-B2 | Bax inhibitors and uses thereof | BAX, TMBIM6, BCL2 | SMN1; SMN2 2633/4885POLB 1716/4885ALDH1A1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.